Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
April 22 2019 - 11:03AM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced the launch of a generic version of VESIcare ®1
(solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
Solifenacin Succinate Tablets are a muscarinic antagonist
indicated for the treatment of overactive bladder with symptoms of
urge urinary incontinence, urgency, and urinary frequency.
Overactive bladder (OAB) is most often characterized by a strong
sudden urge to urinate that is difficult to control.
“About 33 million Americans have overactive bladder.2 We’re
proud to offer another treatment option for this common condition,”
said Brendan O’Grady, EVP and Head of North America Commercial.
With nearly 500 generic medicines available, Teva has the
largest portfolio of FDA-approved generic products on the market
and holds the leading position in first-to-file opportunities, with
over 100 pending first-to-files in the U.S. Currently, one in eight
generic prescriptions dispensed in the U.S. is filled with a Teva
generic product.
VESIcare® Tablets have annual sales of more than $955 million in
the U.S., according to IQVIA data as of February 2019.
About Solifenacin Succinate Tablets
Solifenacin Succinate Tablets are a muscarinic antagonist
indicated for the treatment of overactive bladder with symptoms of
urge urinary incontinence, urgency, and urinary frequency.
IMPORTANT SAFETY INFORMATION
Solifenacin Succinate Tablets are contraindicated in patients
with urinary retention, gastric retention, uncontrolled
narrow-angle glaucoma, and in patients who have demonstrated
hypersensitivity to the drug.
Angioedema of the face, lips, tongue, and/or larynx have been
reported with solifenacin. Angioedema associated with upper airway
swelling may be life threatening. Anaphylactic reactions have been
reported rarely in patients treated with solifenacin succinate.
Solifenacin Succinate Tablets should not be used in patients with a
known or suspected hypersensitivity to solifenacin succinate.
Solifenacin succinate should be administered with caution to
patients with clinically significant bladder outflow obstruction
because of the risk of urinary retention. Solifenacin succinate
should be used with caution in patients with decreased
gastrointestinal motility. Solifenacin succinate is associated with
anticholinergic central nervous system (CNS) effects. A variety of
CNS anticholinergic effects have been reported, including headache,
confusion, hallucinations and somnolence. Solifenacin succinate
should be used with caution in patients being treated for
narrow-angle glaucoma.
Solifenacin succinate should be used with caution in patients
with hepatic or renal impairment. Doses of solifenacin succinate
greater than 5 mg are not recommended in patients with moderate
hepatic impairment or severe renal impairment. Solifenacin
succinate is not recommended for patients with severe hepatic
impairment. Solifenacin succinate should be used with caution in
patients with a known history of QT prolongation or patients who
are taking medications known to prolong the QT interval.
In clinical trials, the most common adverse reactions (> 4%
and > placebo) were dry mouth, and constipation at both 5 mg and
10 mg doses; and urinary tract infection, and blurred vision at the
10 mg dose.
For more information, please see accompanying Full Prescribing
Information. A copy may be requested from Teva U.S. Medical
Information at 888-TEVA-USA (888-838-2872), druginfo@tevapharm.com,
or Teva’s Public Relations or Investor Relations contacts.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 35,000
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding the launch and potential benefits of the generic version
of VESIcare®, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to:
- The uncertainty of the commercial
success of our generic version of VESIcare ®, including due to a
potential launch of an authorized generic version;
- our ability to successfully compete in
the marketplace, including: that we are substantially dependent on
our generic products; competition for our specialty products,
especially COPAXONE®, our leading medicine, which faces competition
from existing and potential additional generic versions and
orally-administered alternatives; the uncertainty of commercial
success of AJOVY® or AUSTEDO®; competition from companies with
greater resources and capabilities; efforts of pharmaceutical
companies to limit the use of generics, including through
legislation and regulations; consolidation of our customer base and
commercial alliances among our customers; the increase in the
number of competitors targeting generic opportunities and seeking
U.S. market exclusivity for generic versions of significant
products; price erosion relating to our products, both from
competing products and increased regulation; delays in launches of
new products and our ability to achieve expected results from
investments in our product pipeline; our ability to take advantage
of high-value opportunities; the difficulty and expense of
obtaining licenses to proprietary technologies; and the
effectiveness of our patents and other measures to protect our
intellectual property rights;
- our substantial indebtedness, which may
limit our ability to incur additional indebtedness, engage in
additional transactions or make new investments, may result in a
further downgrade of our credit ratings; and our inability to raise
debt or borrow funds in amounts or on terms that are favorable to
us;
- our business and operations in general,
including: failure to effectively execute our restructuring plan
announced in December 2017; uncertainties related to, and failure
to achieve, the potential benefits and success of our new senior
management team and organizational structure; harm to our pipeline
of future products due to the ongoing review of our R&D
programs; our ability to develop and commercialize additional
pharmaceutical products; potential additional adverse consequences
following our resolution with the U.S. government of our FCPA
investigation; compliance with sanctions and other trade control
laws; manufacturing or quality control problems, which may damage
our reputation for quality production and require costly
remediation; interruptions in our supply chain; disruptions of our
or third party information technology systems or breaches of our
data security; the failure to recruit or retain key personnel;
variations in intellectual property laws that may adversely affect
our ability to manufacture our products; challenges associated with
conducting business globally, including adverse effects of
political or economic instability, major hostilities or terrorism;
significant sales to a limited number of customers in our U.S.
market; our ability to successfully bid for suitable acquisition
targets or licensing opportunities, or to consummate and integrate
acquisitions; and our prospects and opportunities for growth if we
sell assets ;
- compliance, regulatory and litigation
matters, including: costs and delays resulting from the extensive
governmental regulation to which we are subject; the effects of
reforms in healthcare regulation and reductions in pharmaceutical
pricing, reimbursement and coverage; governmental investigations
into selling and marketing practices; potential liability for
patent infringement; product liability claims; increased government
scrutiny of our patent settlement agreements; failure to comply
with complex Medicare and Medicaid reporting and payment
obligations; and environmental risks;
- other financial and economic risks,
including: our exposure to currency fluctuations and restrictions
as well as credit risks; potential impairments of our intangible
assets; potential significant increases in tax liabilities; and the
effect on our overall effective tax rate of the termination or
expiration of governmental programs or tax benefits, or of a change
in our business;
and other factors discussed in our Annual Report on Form 10-K
for the year ended December 31, 2018, including the sections
thereof captioned "Risk Factors." Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information.
1 VESIcare® is a registered trademark of Astellas Pharma, Inc.2
Urology Care Foundation:
https://www.urologyhealth.org/urologic-conditions/overactive-bladder-(oab)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190422005394/en/
IRUnited StatesKevin C. Mannix(215)
591-8912IsraelRan Meir972 (3) 926-7516PRUnited
StatesKelley Dougherty(973) 658-0237IsraelYonatan
Beker972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024